|
|
News Breaks | | | | February 27, 2013 | | 05:55 EDT |  | RHHBY, RHHBY, JNJ, JNJ, AMGN, AMGN, CELG, CELG, BIIB, BIIB, RGLS, RGLS, MRK, MRK, NVS, NVS, GSK, GSK, BMY, BMY | Biocom to host a conference
3rd Annual Global Life Science Partnering Conference is being held in San Diego, California on February 27-28. | |
|
News For BMY;GSK;NVS;MRK;RGLS;BIIB;CELG;AMGN;JNJ;RHHBY From The Last 14 Days Check below for free stories on BMY;GSK;NVS;MRK;RGLS;BIIB;CELG;AMGN;JNJ;RHHBY the last two weeks. |
|
|
| June 18, 2013 | | 19:07 EDT |  | AMGN | On The Fly: After Hours Movers
 Subscribe for More Information | | | 17:25 EDT | | AMGN | Amgen reports 7.58% stake in Cytokinetics
Subscribe for More Information | | | 16:00 EDT |  | MRK | Options Update; June 18, 2013
Subscribe for More Information | | | 08:37 EDT |  | GSK, MRK | Drug companies turn to microchips to test medicines, WSJ reports
Subscribe for More Information | | | 07:34 EDT |  | JNJ | Medivation pullback a buying opportunity, says JPMorgan
Subscribe for More Information | | | 07:22 EDT | | NVS | Citigroup to host a conference
Subscribe for More Information | | | 07:13 EDT | | GSK | Aspen in talks buy GSK's Arixtra, Fraxiparine brands
Subscribe for More Information | | | 07:07 EDT | | GSK | GlaxoSmithKline receives offer for thrombosis brands from Aspen
GlaxoSmithKline said it received an offer for its thrombosis brands and Notre-Dame de Bondeville site from Aspen Global. A period of exclusivity has been agreed with Aspen. The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra and Fraxiparine brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees, GSK said. "The proposed transaction is aligned to GSK's strategy of focusing on products with the most growth potential and the delivery of its pipeline," the company added. | | | June 17, 2013 | | 16:20 EDT |  | JNJ | On The Fly: Closing Wrap
Stocks on Wall Street were higher following a session dominated by speculation over what is next for the Federal Reserve. The averages trimmed their gains after an article by the Financial Times suggested the Fed would signal a tapering of its pace of asset purchases at its Wednesday press conference. The upward trend resumed after the article's author said the report was based on opinion and that, "The Fed does not leak anything to any journalist to steer markets - especially during blackout." ECONOMIC EVENTS: In the U.S., the New York Fed Empire State Survey for June came in at 7.40, versus expectations for a 0 reading. The NAHB housing market confidence index for June rose to 52, versus the forecast for a more modest climb to 45 from its prior 44 reading. In Europe, Germany's Bundesbank said economic indicators for April pointed to robust growth in the second quarter and business sentiment improved in May, though warned of signs that growth in Europe's largest economy would slow over the summer. COMPANY NEWS: Netflix (NFLX) and DreamWorks (DWA) both climbed after announcing a major content deal. Under the agreement, DreamWorks will provide over 300 hours of content to Netflix, which the TV and movie service expects to start broadcasting next year. After the announcement, Netflix rose $15.24, or 7.12%, to $229.23, while DreamWorks added 93c, or 4.08%, to $23.74. MAJOR MOVERS: Among the notable gainers was Kandi Technologies (KNDI), up $1.53, or 24.4%, to $7.80 after saying it will deploy 5K-10K pure electric vehicles in China within the first year of launch. Also higher were shares of ViroPharma (VPHM), up $1.71, or 6.3%, to $28.87 after Reuters said the company has attracted takeover interest, though the company is not pursuing a sale. Among the noteworthy losers was Terex (TEX), down $2.45, or 7.72%, to $29.29 after the company lowered it fiscal year earnings view. Also lower was Medivation (MDVN), down $3.45, or 6.78%, to $47.41 after Johnson & Johnson (JNJ) acquired the company's competitor, privately held Aragon Pharmaceuticals. INDICES: The Dow was up 109.67, or 0.73%, to 15,179.85; the Nasdaq was up 28.57, or 0.83%, to 3,452.13; and the S&P 500 was up 12.31, or 0.76%, to 1,639.04. | | | 12:29 EDT | | JNJ | On The Fly: Midday Wrap
Subscribe for More Information | | | | 12:28 EDT | | JNJ | Medivation retreats after J&J beefs up prostate cancer slate
Subscribe for More Information | | | 12:08 EDT | | JNJ | J&J deal not negative for Medivation, says Citigroup
Subscribe for More Information | | | 08:54 EDT | | BIIB | Biogen weekly MS drug scripts up 39%, says Citigroup
Subscribe for More Information | | | 08:36 EDT | | MRK | InSite Vision to join Merck, Pfizer patent suit against Mylan
InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. | | | 08:04 EDT | | JNJ | Johnson & Johnson agrees to acquire Aragon Pharmaceuticals
Johnson & Johnson announced a definitive agreement to acquire Aragon Pharmaceuticals, a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. The acquisition includes Aragon's androgen receptor antagonist program. Aragon's lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase 2 development for castration resistant prostate cancer. Under the terms of the agreement, Johnson & Johnson will make an upfront cash payment of $650M, plus additional contingent payments of up to $350M based on reaching predetermined milestones. The transaction is expected to close in the third quarter of 2013. | | | 07:28 EDT | | NVS, BMY | Cambridge Healthtech Institute to host a conference
Subscribe for More Information | | | 07:25 EDT | | NVS | Leerink to host a conference
Subscribe for More Information | | | 05:44 EDT | | CELG | Celgene awarded marketing authorisation for Revlimid from EC
Subscribe for More Information | | | June 16, 2013 | | 14:45 EDT | | JNJ | J&J's Depuy Synthes unit wins $16M in patent case, Bloomberg says
Subscribe for More Information | | | 14:09 EDT | | NVS | Jakafi improved overall survival in Phase III trial of patients with myelofibros
Incyte (INCY) announced results from two ongoing clinical trials of Jakafi, ruxolitinib, an oral JAK1 and JAK2 inhibitor that is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis, MF, that were presented at the 18th Congress of the European Hematology Associationm EHA, in Stockholm, Sweden. In a three-year follow-up analysis of the Phase III COMFORT-II study, treatment with Jakafi, which is marketed as Jakavi by Novartis (NVS) outside the United States, was associated with improved overall survival and sustained reductions in spleen size compared to best available therapy. In a separate exploratory analysis of bone marrow fibrosis data from an ongoing Phase I/II single-arm, open-label clinical trial, by 48 months of treatment, Jakafi stabilized or reversed fibrosis of the bone marrow in 56 percent and 22 percent, respectively, of patients with MF, a magnitude of an effect not seen historically with best available therapy. | | |
|
|
|
|
|
|
